Abstract

BackgroundDetailed characteristics of Hepatitis C virus (HCV) infection in Burkina Faso are scarce. The main aim of this study was to assess HCV seroprevalence in various settings and populations at risk in Burkina Faso between 1990 and 2020. Secondary objectives included the prevalence of HCV Ribonucleic acid (RNA) and the distribution of HCV genotypes.MethodsA systematic database search, supplemented by a manual search, was conducted in PubMed, Web of Science, Scopus, and African Index Medicus. Studies reporting HCV seroprevalence data in low and high-risk populations in Burkina Faso were included, and a random-effects meta-analysis was applied. Risk of bias was assessed using the Joanna Briggs institute checklist.ResultsLow-risk populations were examined in 31 studies involving a total of 168,151 subjects, of whom 8330 were positive for HCV antibodies. Six studies included a total of 1484 high-risk persons, and 96 had antibodies to HCV. The pooled seroprevalence in low-risk populations was 3.72% (95% CI: 3.20–4.28) and 4.75% (95% CI: 1.79–8.94) in high-risk groups. A non-significant decreasing trend was observed over the study period. Seven studies tested HCV RNA in a total of 4759 individuals at low risk for HCV infection, and 81 were positive. The meta-analysis of HCV RNA yielded a pooled prevalence of 1.65% (95% CI: 0.74–2.89%) in low-risk populations, which is assumed to be indicative of HCV prevalence in the general population of Burkina Faso and suggests that about 301,174 people are active HCV carriers in the country. Genotypes 2 and 1 were the most frequent, with 60.3% and 25.0%, respectively.ConclusionsHCV seroprevalence is intermediate in Burkina Faso and indicates the need to implement effective control strategies. There is a paucity of data at the national level and for rural and high-risk populations. General population screening and linkage to care are recommended, with special attention to rural and high-risk populations.

Highlights

  • Detailed characteristics of Hepatitis C virus (HCV) infection in Burkina Faso are scarce

  • The WHO requires a confirmatory test by detecting HCV ribonucleic acid (HCV Ribonucleic acid (RNA)) or core antigen (HCVcAg) [8]

  • HCV seroprevalence was highest among sex workers (9.85%, 95% CI: 6.82–13.34) and Human Immunodeficiency Virus (HIV) patients (7.76%, 95% CI: 4.63–11.59)

Read more

Summary

Introduction

Detailed characteristics of Hepatitis C virus (HCV) infection in Burkina Faso are scarce. Secondary objectives included the prevalence of HCV Ribonucleic acid (RNA) and the distribution of HCV genotypes. Hepatitis C virus (HCV) infection is a bloodborne disease which is globally distributed that mainly affects developing countries. Ouoba et al BMC Infect Dis (2021) 21:1126 high-risk populations, including people who inject drugs (PWID) and men who have sex with men (MSM) [3]. Since no vaccine is available to prevent HCV infection and its chronic consequences, screening and treatment of cases using effective direct-acting antivirals (DAA) are required [6]. The WHO requires a confirmatory test by detecting HCV ribonucleic acid (HCV RNA) or core antigen (HCVcAg) [8]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call